Related Experiment Video
Updated: Sep 16, 2025

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
Treatment With Inclisiran During Peritoneal Dialysis
Elena Sani1, Elisabetta Rinaldi1, Maria Giovanna Lupo2
1Division of Endocrinology, Diabetes and Metabolism, University of Verona, Verona, Italy.
Background:
Inclisiran is a small interfering RNA that prevents PCSK9 (proprotein convertase subtilisin/kexin type 9) synthesis, lowering low-density lipoprotein cholesterol. In ORION trials, efficacy and safety outcomes of inclisiran were similar among different renal impairment degrees, but no data are available in peritoneal dialysis (PD).
Case Summary:
We present the case of a 47-year-old woman with severe and recurrent cardiovascular disease and end-stage renal disease on PD. Following inclisiran injection, low-density lipoprotein cholesterol levels significantly decreased by 56.2% at 3 months. Reductions in apolipoprotein B, lipoprotein(a), and PCSK9 concentration were observed. No side effects were reported.
Discussion:
This report suggests, for the first time, that inclisiran may represent a potential treatment option for lipid control in patients undergoing PD, with results comparable to those reported in clinical trials and a good tolerability profile.
Take-Home Message:
Inclisiran is a potential lipid-lowering therapy in patients on peritoneal dialysis.
Related Concept Videos
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal Dialysis I: Introduction and Procedure
Peritoneal Dialysis III: Nursing Management
Hemodialysis II: Procedure and Complications
Acute Kidney Injury V: Interprofessional Care
Dialysis

